Pure Global

A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptomatic knee osteoarthritis - Trial 2021-002795-39

Access comprehensive clinical trial information for 2021-002795-39 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Farmacéutica S.A. and is currently Ongoing. The study focuses on Knee osteoarthritis.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2021-002795-39
Ongoing
Trial Details
EU Clinical Trials Register • 2021-002795-39
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptomatic knee osteoarthritis

Study Focus

Knee osteoarthritis

Sponsor & Location

Novartis Farmacéutica S.A.

Novartis Pharma AG

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

•Painful ipsilateral hip OA defined as a Pain NRS >/3 on the majority of days in the last 3 months prior to Screening 1, as reported by the patient.

ICD-10 Classifications

Chronic instability of knee
Gonarthrosis [arthrosis of knee]
Other hypertrophic osteoarthropathy
Dislocation, sprain and strain of joints and ligaments of knee
Patellofemoral disorders

Data Source

EU Clinical Trials Register

2021-002795-39

Non-Device Trial